PubRank

T Iwatsubo

Author PubWeight™ 161.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005 21.67
2 Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998 5.47
3 Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995 2.90
4 DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007 2.86
5 Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998 2.47
6 Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 2000 2.27
7 Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998 2.25
8 Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 1997 2.15
9 Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998 1.93
10 Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ 1998 1.92
11 Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 1998 1.90
12 A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem 1999 1.87
13 Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 2001 1.82
14 Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001 1.81
15 Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 1996 1.78
16 Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998 1.76
17 The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci U S A 1997 1.69
18 Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 2000 1.66
19 A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) Ann Neurol 2000 1.65
20 Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. Development 1999 1.56
21 Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 2009 1.51
22 Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 2000 1.48
23 Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett 1999 1.42
24 Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 1999 1.38
25 Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001 1.34
26 Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Ann Neurol 1996 1.32
27 High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 1994 1.24
28 Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 2000 1.24
29 Intercellular localization of acid invertase in tomato fruit and molecular cloning of a cDNA for the enzyme. Plant Cell Physiol 1993 1.20
30 G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science 1996 1.15
31 The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. Neuropathol Appl Neurobiol 2004 1.14
32 Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet 2001 1.14
33 Lack of the carboxyl terminal sequence of tau in ghost tangles of Alzheimer's disease. Brain Res 1993 1.14
34 Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996 1.12
35 Paired helical filaments in astrocytes: electron microscopy and immunohistochemistry in a case of atypical Alzheimer's disease. Acta Neuropathol 1992 1.11
36 The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 1997 1.10
37 Pick's disease is associated with mutations in the tau gene. Ann Neurol 2000 1.10
38 The nonconserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced abeta 42 production mediated by familial early onset Alzheimer's disease-linked PS variants. J Biol Chem 2000 1.08
39 Caveolin-3 upregulation activates beta-secretase-mediated cleavage of the amyloid precursor protein in Alzheimer's disease. J Neurosci 1999 1.08
40 Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett 1997 1.08
41 Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett 1999 1.08
42 Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol 2001 1.08
43 Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. Am J Pathol 1996 1.07
44 Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett 2001 1.06
45 Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004 1.06
46 Pathobiology of the Lewy body. Adv Neurol 1999 1.05
47 C terminus of presenilin is required for overproduction of amyloidogenic Abeta42 through stabilization and endoproteolysis of presenilin. J Neurosci 1999 1.04
48 Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and lewy body pathology. Acta Neuropathol 2000 1.04
49 Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Neurodegeneration 1996 1.04
50 Rapid and reversible changes in dendrite morphology and synaptic efficacy following NMDA receptor activation: implication for a cellular defense against excitotoxicity. J Cell Sci 2001 1.02
51 Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease? J Neurol Neurosurg Psychiatry 2005 1.01
52 Familial Alzheimer's disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43). Biochem Biophys Res Commun 1996 1.00
53 Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998 0.99
54 Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 1999 0.99
55 Evidence that intramolecular associations between presenilin domains are obligatory for endoproteolytic processing. J Biol Chem 1999 0.98
56 Molecular cloning and characterization of a novel chloride intracellular channel-related protein, parchorin, expressed in water-secreting cells. J Biol Chem 2000 0.98
57 Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol 1998 0.97
58 Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J Neurochem 1998 0.97
59 Relationships in Alzheimer's disease between the extent of Abeta deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen. Neuropathol Appl Neurobiol 2006 0.96
60 Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons. Neuron 1992 0.96
61 Amyloid (Abeta) deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. Ann Neurol 1997 0.96
62 Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol 2013 0.96
63 Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype. Neurosci Lett 2001 0.95
64 Focal appearance of cerebellar torpedoes associated with discrete lesions in the cerebellar white matter. Acta Neuropathol 1992 0.94
65 Localization of D-aspartic acid in elongate spermatids in rat testis. Arch Biochem Biophys 1998 0.94
66 Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis. Ann Neurol 2001 0.94
67 Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann Neurol 1997 0.94
68 Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease. Neurosci Lett 1998 0.93
69 Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex. Neuroreport 1997 0.93
70 Molecular cloning of a novel basic helix-loop-helix protein from the rat brain. Biochem Biophys Res Commun 1996 0.93
71 Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Abeta42. J Biol Chem 1998 0.92
72 Molecular cloning and expression of the novel splice variants of K(+) channel-interacting protein 2. Biochem Biophys Res Commun 2001 0.91
73 Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 2000 0.91
74 Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as 'cotton wool' plaques. Neuropathol Appl Neurobiol 2001 0.91
75 The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and gamma-secretase activities of presenilins. J Biol Chem 2001 0.91
76 Localization of alpha-tocopherol transfer protein in rat brain. Neurosci Lett 1998 0.91
77 The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. J Med Genet 2001 0.91
78 Subcellular compartment and molecular subdomain of beta-amyloid precursor protein relevant to the Abeta 42-promoting effects of Alzheimer mutant presenilin 2. J Biol Chem 2001 0.91
79 Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. Neuropathol Appl Neurobiol 2006 0.90
80 Bunina bodies in neurons of the medullary reticular formation in amyotrophic lateral sclerosis. Acta Neuropathol 1993 0.89
81 Emergence of D-aspartic acid in the differentiating neurons of the rat central nervous system. Brain Res 1998 0.89
82 Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease. J Med Genet 2003 0.89
83 The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett 2002 0.88
84 Frontal pure agraphia for kanji or kana: dissociation between morphology and phonology. Neurology 1997 0.88
85 Amyloid plaques in Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex contain species of A beta similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging. Acta Neuropathol 1998 0.87
86 Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. Acta Neuropathol 1995 0.87
87 Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica 2007 0.86
88 Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease. Lancet 1994 0.86
89 Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. Neuroreport 1999 0.86
90 Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol 2001 0.86
91 Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease. Neuropathol Appl Neurobiol 2003 0.85
92 Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). Neurodegeneration 1996 0.84
93 D-aspartate uptake into cultured rat pinealocytes and the concomitant effect on L-aspartate levels and melatonin secretion. Biochem Biophys Res Commun 1998 0.84
94 Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer's disease. Neurosci Lett 2002 0.84
95 Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans. Neurosci Lett 1999 0.84
96 A FE65 polymorphism associated with risk of developing sporadic late-onset alzheimer's disease but not with Abeta loading in brains. Neurosci Lett 2000 0.83
97 An intronic polymorphism in the presenilin-1 gene does not influence the amount or molecular form of the amyloid beta protein deposited in Alzheimer's disease. Neurosci Lett 1997 0.83
98 Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 2007 0.83
99 Atypical amyloid (A beta) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. Acta Neuropathol 1996 0.82
100 Comparable amyloid beta-protein (A beta) 42(43) and A beta 40 deposition in the aged monkey brain. Neurosci Lett 1996 0.82
101 Primary progressive aphasia with focal glial tauopathy. Neuropathol Appl Neurobiol 2000 0.81
102 D-aspartate localization in the rat pituitary gland and retina. Brain Res 1999 0.81
103 Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype. J Neurol Neurosurg Psychiatry 2006 0.81
104 BetaAPP gamma-secretase and SREBP site 2 protease are two different enzymes. Neuroreport 1998 0.81
105 In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 2001 0.81
106 Immunohistochemical localization of D-aspartate in the rat pineal gland. Biochem Biophys Res Commun 1997 0.80
107 Association study of Notch 4 polymorphisms with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004 0.80
108 Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. Neuropathol Appl Neurobiol 1998 0.79
109 Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica 2008 0.79
110 Apoptosis in neurodegenerative diseases. Adv Pharmacol 1997 0.79
111 Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology 2002 0.79
112 The presenilin 1 mutation (M146V) linked to familial Alzheimer's disease attenuates the neuronal differentiation of NTera 2 cells. Biochem Biophys Res Commun 1998 0.78
113 Effects of phenothiazines on the Na+-H+ exchanger of the brush-border membrane from the proximal small intestine of the rabbit. J Pharmacol Exp Ther 1988 0.78
114 The presenilin 2 loop domain interacts with the mu-calpain C-terminal region. Int J Mol Med 1998 0.78
115 Localization, transport, and uptake of D-aspartate in the rat adrenal and pituitary glands. Arch Biochem Biophys 2001 0.78
116 Biosynthesis of D-aspartate in mammalian cells. FEBS Lett 1998 0.78
117 Effects of potential damaging agents on the microclimate-pH in the rat jejunum. J Pharm Sci 1986 0.78
118 [Assessment of anesthesia satisfaction using direct interviews at post-anesthesia clinic]. Masui 2001 0.77
119 D-aspartic acid localization during postnatal development of rat adrenal gland. Biochem Biophys Res Commun 1997 0.77
120 Influence of parameter settings in voxel-based morphometry 8. Using DARTEL and region-of-interest on reproducibility in gray matter volumetry. Methods Inf Med 2014 0.77
121 Functional involvement of the organic cation transporter 2 (rOct2) in the renal uptake of organic cations in rats. J Int Med Res 2008 0.77
122 Disseminated Pneumocystis carinii infection in a hemophiliac patient with acquired immunodeficiency syndrome. Acta Pathol Jpn 1992 0.76
123 A polymorphism within intron 11 of the tau gene is not increased in frequency in patients with sporadic Alzheimer's disease, nor does it influence the extent of tau pathology in the brain. Neurosci Lett 2002 0.76
124 Some unusual responses of astrocytes to ghost tangles in a long duration case of juvenile Alzheimer's disease: an electron microscopic study. J Neurol Sci 1996 0.76
125 Association study of three polymorphisms of TGF-beta1 gene with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002 0.75
126 Molecular interactions between presenilin and calpain: inhibition of m-calpain protease activity by presenilin-1, 2 and cleavage of presenilin-1 by m-, mu-calpain. Int J Mol Med 2000 0.75
127 Single umbilical artery --a review of 37 cases--. Acta Obstet Gynaecol Jpn 1976 0.75
128 Investigation of a colloidal damper. J Colloid Interface Sci 2003 0.75
129 [Co-existence of clinical and immunohistochemical features of polymyositis and myasthenia gravis]. Rinsho Shinkeigaku 1988 0.75
130 The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype. Neurosci Lett 1995 0.75
131 P15 in tibial nerve SEPs as an example of the junctional potential. Electroencephalogr Clin Neurophysiol 1992 0.75
132 Tissue distribution of YM758, a novel If channel inhibitor, in pregnant and lactating rats. Xenobiotica 2008 0.75
133 Novel and global approach of the complex and interconnected phenomena related to the contact line movement past a solid surface from hydrophobized silica gel. J Colloid Interface Sci 2005 0.75
134 Theoretical investigation of an artificial joint with micro-pocket-covered component and biphasic cartilage on the opposite articulating surface. J Biomech Eng 2003 0.75
135 Separation of aromatic isomers on cyclophane-bonded stationary phases. J Chromatogr A 2000 0.75
136 [Chronic inflammatory demyelinating polyradiculoneuropathy of acute onset: relapse after temporary improvement by plasma exchange and longstanding remission by corticosteroid therapy]. Rinsho Shinkeigaku 1989 0.75
137 [Dynamic approach to the normal value, with special reference to glucose tolerance test]. Rinsho Byori 1979 0.75
138 Subpial amyloid plaques in the cerebellum in a case of Alzheimer's disease. Dement Geriatr Cogn Disord 1997 0.75
139 Synthesis and biological activity of N-substituted spiro[benzoxazepine-piperidine] Abeta-peptide production inhibitors. J Enzyme Inhib Med Chem 2008 0.75
140 A case of partial trisomy 2p (region 2p21 to 2pter) derived from a maternal t(2;15)(p21;q26). Jinrui Idengaku Zasshi 1980 0.75
141 Tau accumulation in a patient with pallidonigroluysian atrophy. Neurosci Lett 2001 0.75
142 Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. Toxicol Lett 1995 0.75
143 [Analysis of the drill hole orientation in anterior cruciate ligament reconstruction]. Nihon Seikeigeka Gakkai Zasshi 1995 0.75
144 [Molecular cell biology of presenilins]. Nihon Yakurigaku Zasshi 1999 0.75
145 Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration. J Toxicol Sci 1996 0.75
146 [Bilateral horizontal gaze palsy due to hemi-tegmental lesion in a case of pontine infarction]. Rinsho Shinkeigaku 1988 0.75
147 [Effect of colforsin daropate hydrochloride after cardiopulmonary bypass]. Masui 2001 0.75
148 [On the mechanism of symptomatic development in syringomyelobulbia]. Rinsho Shinkeigaku 1988 0.75